Kimberly-Clark is acquiring Tylenol maker Kenvue in a $48.7 billion cash-and-stock deal, creating a major consumer health goods company if shareholders approve.
A number of prominent hedge funds are likely applauding Monday’s news that Kimberly-Clark Corp. has agreed to acquire Kenvue ...
Kenvue’s stock, which had hit a record low in recent weeks, was headed for its best day ever, while Kimberly-Clark’s stock ...
Potentially huge legal issues are hovering over Kenvue. But Kimberly-Clark, which agreed to buy it for $40 billion, appears ...
Asian shares have retreated despite the big lift in overseas markets from optimism over AI technology. Shares declined ...
Bank of America's stock has lagged behind rivals, notably industry leader JPMorgan Chase, over the past five years. Financial Services Roundup: Market Talk Find insight on Westpac, Deterra Royalties ...
In this piece, we will look at the stocks Jim Cramer discussed.
Despite a headline beat and decent revenue forecast, the poor reaction to the update from AI and data analytics darling Palantir - whose stock has more than doubled this year on AI excitement and ...
Dow Jones Top Company Headlines at 5 AM ET: Saudi Aramco's Net Profit Rises on Higher Production, Oil Prices | BP ... Third-quarter profit rose compared with the prior three-month period but declined ...
The consumer health and wellness giants are both Dividend Kings, with more than 50 years of consecutive annual payout ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback